Drug Trial Radar · NCT04265755
Biomarker and Genetic Predictors of Erenumab Treatment Response
Last checked: Nov 20, 2026Latest source record: Jun 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,406
Actual
Start
Oct 26, 2020
Primary completion
Jan 18, 2023
Study completion Jan 18, 2023
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Feb 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To explore the relationship between clinical response to erenumab and genetic biomarkers
Conditions
- Migraine
Interventions
ErenumabDrug
Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving at Least a 50% Reduction From Baseline in Mean MMDs Over Months 4, 5, and 6 in Relation to mPRSTime frame: 4-week Baseline Period and the last 3 months (Months 4, 5, and 6) of the 24-week Open-label Treatment Period
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Glostrup Hospital
Glostrup Municipality, Denmark
Thjonustumidstod Rannsoknaverkefna
Reykjavik, Iceland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.